State Street
MNPR icon

State Street’s Monopar Therapeutics MNPR Stock Holding History

State Street’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.84M Buy
88,355
+4,366
+5% +$264K ﹤0.01% 2978
2025
Q4 		$5.48M Buy
83,989
+11,751
+16% +$960K ﹤0.01% 2955
2025
Q3 		$5.9M Buy
72,238
+30,412
+73% +$1.36M ﹤0.01% 2935
2025
Q2 		$1.5M Buy
41,826
+26,012
+164% +$945K ﹤0.01% 3394
2025
Q1 		$576K Buy
+15,814
New +$570K ﹤0.01% 3561

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street's MNPR Position: Q1 2026 in Review

State Street increased its Monopar Therapeutics (MNPR) stake by 5.2% in Q1 2026, buying an estimated $264K and bringing the position to 88,355 shares worth $4.84M. The position accounts for ﹤0.01% of the portfolio, ranked #2978.

State Street first reported a position in MNPR in Q1 2025 and has held it in 5 quarters since. The position peaked at $5.9M in Q3 2025. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • State Street held 88,355 shares of Monopar Therapeutics worth $4.84M as of Q1 2026.
  • State Street bought 4,366 Monopar Therapeutics shares in Q1 2026, an estimated $264K.
  • Monopar Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #2978 holding.
  • State Street first reported a position in Monopar Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • State Street's Monopar Therapeutics position peaked at $5.9M in Q3 2025.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.